...
首页> 外文期刊>Infection and immunity >Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus.
【24h】

Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus.

机译:抗血清对创伤弧菌荚膜多糖-破伤风类毒素结合疫苗的临床前免疫预防和免疫治疗效果。

获取原文

摘要

Vibrio vulnificus is an oyster-associated bacterial pathogen that causes life-threatening fulminating septicemia and necrotizing wound infections in humans. The capsular polysaccharide of V. vulnificus (VvPS) is critical for virulence. Previously we showed that active immunization of mice with a VvPS-tetanus toxoid (VvPS-TTa) conjugate vaccine conferred significantly higher protection against subsequent lethal challenge than immunization with VvPS alone. In the current study, we examined the utility of immunoprophylaxis or immunotherapy with hyperimmune antisera elicited by VvPS-TTa and VvPS-TTb conjugate vaccines prepared by different synthetic schemes. First we demonstrated that the Ribi adjuvant significantly enhanced the murine antibody response (P < or = 0.02) to both conjugates. Subsequently, high-titered polyclonal antisera were raised to VvPS-TTa and VvPS-TTb conjugate vaccines by using Ribi adjuvant or Freund's adjuvants. Antisera were observed to have protective effects when administered before and after acute lethal infection. All animals receiving prophylactic antisera intraperitoneally 24 h before lethal challenge with homologous carbotype 1 were protected, while 73 to 100% of control mice succumbed. Immunotherapy was also effective, with survival rates of 60 to 73% seen among mice when antisera were administered 2 h after bacterial challenge, at a time when symptoms of infection were already apparent. The protective effect of capsular antiserum appeared to be serotype specific. Antisera to the, carbotype 1 VvPS-TTa vaccine did not confer cross-protection against lethal challenge with carbotype 2 V. vulnificus despite partial structural similarity and a weak serological cross-reaction between the two carbotypes. Immune globulins induced by a potential multivalent VvPS conjugate vaccine composed of clinically prevalent carbotypes may have utility in the management of V. vulnificus infections and deserve further evaluation.
机译:创伤弧菌是一种与牡蛎相关的细菌病原体,可导致危及生命的致命性败血病和坏死性伤口感染。创伤弧菌的荚膜多糖(VvPS)对毒力至关重要。以前,我们显示,用VvPS-破伤风类毒素(VvPS-TTa)结合疫苗对小鼠的主动免疫与单独用VvPS免疫相比,对随后的致死性攻击具有更高的保护作用。在当前的研究中,我们研究了通过不同合成方案制备的VvPS-TTa和VvPS-TTb结合疫苗引发的超免疫抗血清的免疫预防或免疫疗法的实用性。首先,我们证明了Ribi佐剂显着增强了鼠对两种结合物的抗体反应(P <或= 0.02)。随后,通过使用Ribi佐剂或Freund佐剂将高滴度多克隆抗血清制成VvPS-TTa和VvPS-TTb缀合物疫苗。在急性致死性感染之前和之后服用抗血清具有保护作用。在致死性攻击同型1型碳前24小时腹膜内接受预防性抗血清的所有动物都受到保护,而73%至100%的对照小鼠则死了。免疫疗法也很有效,在细菌感染后2小时给予抗血清时,在感染症状已经明显的时候,小鼠的存活率为60%至73%。荚膜抗血清的保护作用似乎是血清型特异性的。尽管部分结构相似且两种碳型之间的血清学交叉反应较弱,但对碳型1 VvPS-TTa疫苗的抗血清并未赋予交叉保护以抵抗2型V. vulnificus的致死性攻击。由临床上普遍存在的碳型构成的潜在的多价VvPS偶联疫苗诱导的免疫球蛋白可能在管理V. vulnificus感染中具有效用,值得进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号